No connection

Search Results

KMDA vs RGNX

KMDA
Kamada Ltd.
NEUTRAL
Price
$8.49
Market Cap
$490.9M
Sector
Healthcare
AI Confidence
80%
RGNX
REGENXBIO Inc.
BEARISH
Price
$9.49
Market Cap
$489.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
KMDA
24.26
RGNX
--
Forward P/E
KMDA
14.31
RGNX
-4.32
P/B Ratio
KMDA
1.82
RGNX
4.7
P/S Ratio
KMDA
2.72
RGNX
2.87
EV/EBITDA
KMDA
10.78
RGNX
-3.57

Profitability

Gross Margin
KMDA
42.34%
RGNX
-45.86%
Operating Margin
KMDA
7.95%
RGNX
-189.99%
Profit Margin
KMDA
11.19%
RGNX
-113.75%
ROE
KMDA
7.64%
RGNX
-107.0%
ROA
KMDA
4.37%
RGNX
-21.93%

Growth

Revenue Growth
KMDA
14.5%
RGNX
43.0%
Earnings Growth
KMDA
-14.1%
RGNX
--

Financial Health

Debt/Equity
KMDA
0.04
RGNX
2.54
Current Ratio
KMDA
4.07
RGNX
2.38
Quick Ratio
KMDA
2.2
RGNX
2.27

Dividends

Dividend Yield
KMDA
2.94%
RGNX
--
Payout Ratio
KMDA
0.0%
RGNX
0.0%

AI Verdict

KMDA NEUTRAL

KMDA presents a dichotomy between a fortress-like balance sheet and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health and the Debt/Equity ratio (0.04) is exceptionally low, the stock trades at a significant premium to its Graham Number ($6.06) and Intrinsic Value ($2.45). The attractive PEG ratio (0.63) suggests growth is undervalued, but this is offset by negative YoY earnings growth (-14.10%) and a bearish technical trend.

Strengths
Exceptional liquidity with a Current Ratio of 4.07
Negligible leverage with Debt/Equity at 0.04
Strong PEG ratio (0.63) indicating potential growth undervaluation
Risks
Significant disconnect between current price ($8.49) and Intrinsic Value ($2.45)
Negative earnings growth (-14.10% YoY) despite revenue gains
Bearish technical trend (0/100 score)
RGNX BEARISH

RGNX exhibits significant financial fragility, evidenced by a weak Piotroski F-Score of 3/9 and a lack of deterministic value markers like the Graham Number. While the company shows strong top-line revenue growth of 43%, this is offset by severe profitability deficits, including a profit margin of -113.75% and consistent earnings misses over the last four quarters. The stark divergence between the current price ($9.49) and the analyst target ($27.82) suggests a speculative valuation based on future pipeline success rather than current fundamentals. High debt-to-equity (2.54) and bearish insider sentiment further compound the risk profile.

Strengths
Strong year-over-year revenue growth of 43%
Healthy short-term liquidity with a current ratio of 2.38
Significant positive analyst sentiment with a target price of $27.82
Risks
Severe operational losses with an operating margin of -189.99%
Weak financial health indicated by a Piotroski F-Score of 3/9
High leverage with a Debt/Equity ratio of 2.54

Compare Another Pair

KMDA vs RGNX: Head-to-Head Comparison

This page compares Kamada Ltd. (KMDA) and REGENXBIO Inc. (RGNX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile